{
    "clinical_study": {
        "@rank": "30259", 
        "acronym": "CURTAXEL", 
        "arm_group": [
            {
                "arm_group_label": "Curcumin", 
                "arm_group_type": "Experimental", 
                "description": "curcumine capsule"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus\n      Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic\n      castration resistant. Assess time to progression (time to progression) of metastatic disease\n      (from first day of treatment in the trial)."
        }, 
        "brief_title": "Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)", 
        "condition": "Prostate Cancer Metastatic Castration Resistant", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient older than 18 years.\n\n          -  Performance status \u2264 2 according to the WHO criteria.\n\n          -  Life expectancy> 3 months.\n\n          -  Patient in hormonal blockade based on surgical castration by orchiectomy or\n             pulpectomy, medical or agonist or antagonists of LHRH associated or not with\n             anti-androgens or any other treatment that blocks the fraction of non-gonadal\n             testosterone, resulting in a testosterone <0.5 ng / mL.\n\n          -  Patient with adenocarcinoma of the prostate and histologically proven metastatic\n             castration-resistant stage, defined by: objective progression of at least one\n             measurable tumor target and / or assessable by RECIST, and / or increase in PSA\n             (\"rising PSA\").\n\n          -  Satisfactory biological functions (renal, hepatic and hematologic)\n\n          -  Patient who signed the consent for participation before entering the study.\n\n          -  Affiliation to a social security scheme (or be the beneficiary of such a plan) under\n             the terms of the law of 9 August 2004.\n\n        Exclusion Criteria:\n\n          -  Age <18 years.\n\n          -  Performance status> 2 according to the WHO criteria.\n\n          -  Patient deprived of liberty or under guardianship, patient with (the) condition (s)\n             psychological, family, social or geographic may interfere with the proper conduct of\n             the study.\n\n          -  Diagnosis of a second malignancy in the past 5 years, with the exception of a basal\n             cell skin cancer considered cured.\n\n          -  Patient with brain metastases at initial assessment.\n\n          -  Patient with another pathology deemed incompatible with the inclusion in the\n             protocol.\n\n          -  Laboratory tests inadequate.\n\n          -  History of malabsorption syndrome or extensive resection of the upper digestive\n             tract.\n\n          -  Uncontrolled intercurrent infection.\n\n          -  Pathology autoimmune and / or chronic active inflammation.\n\n          -  peripheral neuropathy grade 2 according to the criteria of the National Cancer\n             Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0).\n\n          -  History of allergy to polysorbate 80.\n\n          -  Treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within\n             three weeks.\n\n          -  Concomitant with a drug test or participation in another clinical trial within <30\n             days treatment.\n\n          -  Regular Taking dietary supplements."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095717", 
            "org_study_id": "2013-002138-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "Curcumin", 
                "intervention_name": "Curcumin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Curcumin", 
                    "Placebo"
                ], 
                "intervention_name": "Taxotere", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Curcumin", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "M\u00e9lanie Pouget", 
                    "phone": "+33(0) 4 63 66 33 37"
                }, 
                "facility": {
                    "address": {
                        "city": "Beaumont", 
                        "country": "France"
                    }, 
                    "name": "Clinique de la Chataigneraie"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "m\u00e9lanie Pouget", 
                    "phone": "+33(0) 4 63 66 33 37"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France"
                    }, 
                    "name": "Centre Jean Perrin"
                }, 
                "investigator": {
                    "last_name": "Hakim Mahammedi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "M\u00e9lanie Pouget", 
                    "phone": "+33(0)4 63 66 33 37"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Puy en velay", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier Emile Roux"
                }, 
                "investigator": {
                    "last_name": "Brigitte Monange", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "brigitte Lanscotte", 
                    "phone": "+33(0)3 26 50 41 83"
                }, 
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "Institut Jean Godinot"
                }, 
                "investigator": {
                    "last_name": "Jean Christophe Eymard", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "melanie.pouget@cjp.fr", 
            "last_name": "M\u00e9lanie Pouget", 
            "phone": "+33(0)463663337"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: ANSM -Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial). Progression was defined as an increase (of) injury (s) tumor (s) (RECIST) or an increase in PSA levels (\u2265 25% and \u2265 2ng/ml increase) or the appearance of new lesions metastatic (at least 2 new lesions for bone lesions).\nFrom date of randomization until the date of first documented progression or date of death from any cause", 
            "measure": "Time to progression", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed post treatment. From date of randomization until the date of first documented progression or date of death from any cause"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the PSA response (50% decrease compared to the initial value)", 
                "measure": "PSA response", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented PSA progression or date of death from any cause"
            }, 
            {
                "description": "Evaluate the objective tumor response rate (CR + PR) by RECIST.", 
                "measure": "objective tumor response rate", 
                "safety_issue": "No", 
                "time_frame": "participants will be evaluated at the end of the treatment (randomization + an expected average of 4 months)"
            }, 
            {
                "description": "Assess the safety (adverse events) of the combination Taxotere/ curcumin.", 
                "measure": "safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "patients will be followed for the duration of the treatment, an expected average of 4 months"
            }, 
            {
                "description": "Assess pain in the short questionnaire on pain (QCD)", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed at Cycle1,3,6 of chemotherapy and post treatment (+1months after the end of the treatment)"
            }, 
            {
                "description": "Assess serum neuroendocrine markers", 
                "measure": "neuroendocrine markers", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of the treatment, an expected average of 4 months"
            }, 
            {
                "description": "Evaluate overall survival (between inclusion and death whatever the cause)", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "from date of randomization until the date of death from any cause"
            }, 
            {
                "description": "Evaluate the anti-angiogenic activity of the association Taxotere \u00ae plus curcumin", 
                "measure": "anti-angiogenic activity", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed at each Cycle of chemotherapy ( + inclusion) , an expected average of 4 months"
            }, 
            {
                "description": "Assess the compliance by curcumin treatment / placebo orally", 
                "measure": "compliance", 
                "safety_issue": "No", 
                "time_frame": "patients will be followed for the duration of the treatment, an expected average of 4 months"
            }
        ], 
        "source": "Centre Jean Perrin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Jean Perrin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}